Cyclic peptide-capped gold nanoparticles for enhanced siRNA delivery

Area of Science:

• Biotechnology
• Nanomedicine
• Molecular Biology

Background:

• Cyclic peptides offer potential as drug delivery vehicles.
• Peptide-capped gold nanoparticles can be synthesized for enhanced functionality.
• Efficient delivery of small interfering RNA (siRNA) is crucial for gene silencing therapies.

Purpose of the Study:

• To evaluate the efficacy of a homochiral cyclic peptide, [WR]5, and its gold nanoparticles ([WR]5-AuNPs) for delivering siRNA into human cervix adenocarcinoma (HeLa) cells.
• To compare the cellular uptake and toxicity of [WR]5 and [WR]5-AuNPs as siRNA carriers against existing systems.

Main Methods:

• Synthesis of peptide-capped gold nanoparticles using HAuCl4 and [WR]5.
• Incubation of HeLa cells with fluorescence-labeled siRNA in the presence of [WR]5 and [WR]5-AuNPs.
• Flow cytometry analysis to quantify intracellular siRNA uptake.
• Comparative toxicity assays against Lipofectamine.

Main Results:

• Intracellular uptake of siRNA was enhanced 2-fold by [WR]5 and 3.8-fold by [WR]5-AuNPs compared to siRNA alone after 24 hours.
• [WR]5 and [WR]5-AuNPs demonstrated lower cellular toxicity than Lipofectamine.
• The peptide and its gold nanoparticles serve as effective carriers for siRNA delivery.

Conclusions:

• The cyclic peptide [WR]5 and its gold nanoparticle conjugate ([WR]5-AuNPs) are efficient and less toxic carriers for siRNA delivery into HeLa cells.
• These peptide-based nanocarriers represent a promising alternative to conventional delivery systems like Lipofectamine for gene therapy applications.
• Further research into peptide-based nanocarriers could advance targeted gene silencing strategies.